# Alan Walts

> Alan Walts is a seed investor at Aura Biosciences (Boston) backing Medical and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aura Biosciences](https://shizune.co/investors/profile/aura-biosciences)
- Location: Boston, United States
- Total investments: 2
- Last investment: Oct 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alan-walts-b4664045/

Alan Walts is a seed investor at Aura Biosciences in Boston focused on Medical and Health Care. Alan Walts - Board Member @ Aura Biosciences

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PIC Therapeutics | PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectivelyblocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States. | $35M | Series A | Oct 19, 2022 |  |
| PIC Therapeutics | PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectivelyblocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States. | $5M | Seed | Apr 15, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Harrington Discovery Institute at University Hospitals](https://shizune.co/investors/profile/harrington-discovery-institute-at-university-hospitals) — VC Fund, 1 deal together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 1 deal together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together

## About Aura Biosciences

VC Fund · Cambridge, United States

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

5 contacts available at Aura Biosciences.

| Name | Title | Profile |
| --- | --- | --- |
| Alan Walts | Board Member | https://shizune.co/investors/profile/alan-walts-d3ea |
| Cadmus Rich | Chief Medical Officer | https://shizune.co/investors/profile/cadmus-rich |
| Conor Kilroy | Chief Legal Officer and Secretary | https://shizune.co/investors/profile/conor-kilroy-d06b |
| Denis O’Shaughnessy | Vice President of Clinical Development | https://shizune.co/investors/profile/denis-oshaughnessy |
| Elisabet de los Pinos | Founder and CEO | https://shizune.co/investors/profile/elisabet-de-los-pinos |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Alan Walts invest in?

Alan Walts invests primarily in Medical, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alan Walts last invest?

The most recent investment recorded for Alan Walts closed in Oct 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co